Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 168

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 168
---
 challenges their validity or,
in relation to a particular Product and a particular Territory at any time, because the Licensee has made a determination that it no longer
wishes to develop and/or commercialize the Product in that country in the Territory. The CMS License Agreement also includes customary
indemnification for a transaction of this type.

Sales and Marketing

We do not currently have any
internal sales and marketing organization or distribution capabilities.

Research and Development

We have leased a laboratory
in Cardiff, Wales in which we are able to undertake basic formulation and analytical work.

Intellectual Property

Our success depends in large
part on our ability to obtain and maintain proprietary protection for our product candidates (and products derived therefrom), technology
and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
We strive to protect the proprietary technology that we believe is important to our business by, among other methods, seeking and maintaining
patents, where available, that are intended to cover our product candidates (and products derived therefrom), compositions and formulations,
their methods of use and processes for their manufacture and any other inventions that are commercially important to the development of
our business. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and
maintain our proprietary and competitive position.

| 85 |

We have developed a strong
intellectual property base globally, comprising patents, know-how, and trade secrets. Currently, we have 53 granted patents, seven applications
in process, in each case covering all major world markets, and 14 separate patent families covering all major regions. We continue to
strengthen our patent portfolio by strategically submitting new patents and divisional patent applications based on our active research
and development activities. Central to our business are our three intellectual property technologies that are designed to enable the targeted
delivery, i.e. right place, and controlled sustained release, i.e. right time, of existing therapeutic drugs. These technologies have
broad applications in multiple therapeutic areas and offer the potential to create multiple revenue opportunities.

Patent rights have been granted
in all the major world markets, including Europe, the United States and Japan, or the Key Markets. The granted patents and pending patent
applications in our patent families are owned solely by us, co-owned with other parties or in-licensed to us. These include patents related
to methods of use of eRapa, tolimidone and MTX110